KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer

BackgroundKRAS mutations, present in over 40% of metastatic colorectal cancer (mCRC), are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a cysteine residue for which drugs have been developed. Published data on this specific mutation are conflicting; thus, we studied...

詳細記述

書誌詳細
主要な著者: Emerik Osterlund, Ari Ristimäki, Soili Kytölä, Teijo Kuopio, Eetu Heervä, Timo Muhonen, Päivi Halonen, Raija Kallio, Leena-Maija Soveri, Jari Sundström, Mauri Keinänen, Annika Ålgars, Raija Ristamäki, Halfdan Sorbye, Per Pfeiffer, Luís Nunes, Tapio Salminen, Annamarja Lamminmäki, Markus J. Mäkinen, Tobias Sjöblom, Helena Isoniemi, Bengt Glimelius, Pia Osterlund
フォーマット: 論文
言語:English
出版事項: Frontiers Media S.A. 2022-02-01
シリーズ:Frontiers in Oncology
主題:
colorectal cancer
metastatic
KRAS mutation
KRAS-G12C mutation
population-based
real-world
オンライン･アクセス:https://www.frontiersin.org/articles/10.3389/fonc.2022.826073/full

インターネット

https://www.frontiersin.org/articles/10.3389/fonc.2022.826073/full

類似資料